Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease
NCT00100282
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
125
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer's Disease
Interventions
DRUG:
PPI-1019 (APAN)
Sponsor
PRAECIS Pharmaceuticals Inc.